Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials.

We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt.

Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV.

Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.

Article activity feed